Mirabegron alone or in combination with solifenacin succinate 5 mg can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Mirabegron is not recommended for use in severe uncontrolled hypertensive patients.

Please login to view the rest of this drug profile.

    DRUG REVIEW ARTICLE

    Click on the DRUG REVIEW ARTICLE tab (above) to see a review of mirabegron in the Taylor & Francis journal Expert Opinion on Drug Safety.

    (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 02/21/2025

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric